FORT LAUDERDALE, Fla. — Patients with an active fluocinolone acetonide implant to treat noninfectious intermediate, posterior or panuveitis experienced similar visual acuity outcomes as patients who received systemic corticosteroids plus immunosuppression when indicated, a speaker said here.
“While the implant remains active, it is similar to systemic treatment in visual acuity outcomes,” Thomas A. Albini, MD, said at the Retina World Congress.
The MUST study evaluated the outcomes of approximately 400 patients with noninfectious intermediate, posterior or panuveitis treated
Uncategorized